Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

14.4 -1.44

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

14.33

Max

14.51

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+105% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	57M 1.2B
Ouverture précédente	15.84
Clôture précédente	14.4

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 sept. 2026, 23:56 UTC

Correlated Moves

Macy's Inc shares are lower in after-market trading, influenced by a decline in Kohl's Corp and broader retail sector challenges.

4 sept. 2026, 23:56 UTC

Southern Co. shares traded roughly flat in after-market hours, remaining below their 20-day moving average and near the lower end of their one-month range.

4 sept. 2026, 23:56 UTC

Redwood Trust shares rose in after-market trading, amid rising Treasury yields and stable unemployment. The stock remains below its 20-day moving average.

4 sept. 2026, 23:55 UTC

Mastercraft Boat Holdings Inc shares are higher in after-market hours. No specific news was identified to explain the movement.

4 sept. 2026, 23:55 UTC

TE Connectivity PLC shares are higher in after-market trading. No specific company news was identified to explain this movement.

4 sept. 2026, 23:55 UTC

Ameriprise Financial Inc shares are higher in after-market trading, influenced by stable labor market data and expectations for an interest rate hike.

4 sept. 2026, 23:55 UTC

Incyte Corp shares are higher in after-market hours, reaching an early peak before settling back. No specific news was identified to explain the movement.

4 sept. 2026, 23:55 UTC

Fastenal Co. shares moved higher in after-market trading, recovering from earlier losses amid rising Treasury yields and steady unemployment data.

4 sept. 2026, 23:51 UTC

International Bancshares Corp. shares remained roughly flat during after-market hours, following four consecutive sessions of higher performance. No specific news was identified.

4 sept. 2026, 23:51 UTC

Cytokinetics Inc shares are higher in after-market trading, reaching their highest cumulative return of the day, despite no specific news driving the move.

4 sept. 2026, 23:51 UTC

Tecnoglass Inc shares are trading higher in after-market hours, marking five consecutive sessions of gains. No specific news was identified to explain the movement.

4 sept. 2026, 23:51 UTC

CGI Inc shares are lower in after-market hours, continuing a decline since Friday's close. The stock remains significantly below its 20-day moving average.

4 sept. 2026, 23:51 UTC

CME Group Inc shares are higher in after-market hours, reflecting strong performance as they approach the upper end of their one-month trading range.

4 sept. 2026, 23:51 UTC

Axon Enterprise Inc shares are trading higher in after-market hours. No specific news was identified to explain this movement.

4 sept. 2026, 23:51 UTC

Kohls Corp shares are lower in after-market hours amid weak trading and mixed economic signals, including rising unemployment and slowing wage growth.

4 sept. 2026, 23:51 UTC

Nextera Energy Inc shares are lower in after-market hours, breaking a recent trend of higher daily closes amid a slight uptick in unemployment rates.

4 sept. 2026, 23:51 UTC

EPR Properties shares are higher in after-market hours, reflecting unusual strength despite no specific company news amid mixed economic signals and interest rate expectations.

4 sept. 2026, 23:51 UTC

Tapestry Inc shares are higher in after-market hours, recovering from an early dip. The stock remains below its 20-day moving average.

4 sept. 2026, 23:51 UTC

ECB Set to Announce Deposit Facility Rate Hike Amid Inflation Concerns and Geopolitical Tensions on September 10, 2026.

4 sept. 2026, 23:50 UTC

Wesco International Inc shares are higher in after-market hours, continuing a trend of recent gains and unusual trading activity noted earlier in the session.

4 sept. 2026, 23:50 UTC

Weyerhaeuser Co shares are higher in after-market trading, reflecting an increase since Friday's close, despite remaining below the 20-day moving average.

4 sept. 2026, 23:46 UTC

Antero Midstream Corp. shares showed little change during after-market hours, fluctuating within a narrow range and remaining above the 20-day moving average.

4 sept. 2026, 23:46 UTC

Correlated Moves

US Bancorp shares are lower in after-market trading amid mixed macroeconomic signals and a decline in Live Oak Bancshares, reflecting broader market sentiments.

4 sept. 2026, 23:46 UTC

Biogen Inc shares are lower in after-market hours, with no specific news driving the decline. Broader economic signals are contributing to market uncertainty.

4 sept. 2026, 23:46 UTC

Enovix Corp shares are higher in after-market trading, though no specific news was identified to explain the movement. Broader market dynamics influenced investor sentiment.

4 sept. 2026, 23:45 UTC

Hershey Co. shares gained in after-market trading, reflecting routine performance amid broader market dynamics, despite earlier fluctuations after Friday's close.

4 sept. 2026, 23:45 UTC

First American Financial shares higher in after-market trading, reflecting broader market movements amid shifting expectations for interest rates and recent economic data.

4 sept. 2026, 23:45 UTC

Iron Mountain Inc is trading lower in after-market hours, with no specific news identified. The stock remains near its one-month low and below its 20-day moving average.

4 sept. 2026, 23:45 UTC

Social Media

NIO Inc. CEO William Li discussed "operational quality" in a closed-door meeting. Shares traded roughly flat during after-market hours following the discussion.

4 sept. 2026, 23:45 UTC

Lucid Group Inc. shares are trading lower in after-market hours, continuing a trend of weakness amid broader market declines and remaining below the 20-day moving average.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

105% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 105%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.